Last reviewed: May 15, 2026

Last updated: May 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Zealthy and Hers represent two distinct telehealth models for GLP-1 access, each with different clinical assessment strategies. Zealthy emphasizes genetic and biomarker analysis as part of its platform, while Hers focuses on straightforward telehealth consultation and prescription delivery. Recent data shows that patients with personalized treatment guidance experience higher medication adherence rates compared to standard care approaches.

Both platforms serve growing demand for convenient GLP-1 access, yet their underlying approaches to patient matching differ significantly. This matters because genetic predispositions in GLP-1 receptor (GLP1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) pathways may influence individual response patterns. PlexusDx's precision-wellness model prioritizes genetic context alongside clinical evaluation, offering compounded GLP-1 options that patients can explore with informed providers.

How Zealthy and Hers Structure GLP-1 Telehealth Access

Zealthy integrates genetic and biomarker screening into its intake process, aiming to identify candidates whose metabolic and genetic profiles suggest GLP-1 suitability. The platform collects DNA samples and bloodwork to assess key variants and baseline health markers before matching patients with prescribers. This upfront profiling differentiates Zealthy from simpler telehealth models that rely primarily on clinical history.

Hers takes a more traditional telehealth approach, connecting patients with licensed prescribers via video consultation who assess eligibility based on clinical criteria and patient-reported health data. Hers does not require genetic testing as part of standard intake. The platform emphasizes speed and accessibility, positioning itself as a direct-to-consumer option for patients who already know they want GLP-1 therapy or have prior experience with these medications.

Clinical Framework Comparison: Assessment and Matching

Understanding how each platform evaluates GLP-1 candidacy reveals important differences in clinical rigor and personalization depth. Zealthy's genetic component targets metabolic heterogeneity—the reality that patients respond differently to GLP-1 based on underlying biology. Hers prioritizes rapid access for motivated candidates without genetic prerequisite testing.

Platform Feature	Zealthy Approach	Hers Approach	Clinical Relevance
Genetic Testing	Included in intake; analyzes GLP1R, GIPR, FTO variants	Optional; not standard in workflow	Genetic variants may contextualize individual peptide pathway function
Biomarker Assessment	Fasting glucose, insulin, lipid panel, HbA1c at baseline	Relies on patient-reported history; lab optional	Baseline biomarkers guide medication selection and monitoring
Prescriber Matching	Algorithm-driven based on genetic + clinical profile	Direct assignment to available prescriber	Precision matching may improve adherence and satisfaction
Medication Options	Multiple GLP-1 agents available based on profile	Primary focus on semaglutide (Wegovy, Ozempic) options	Personalized options vs standardized formulary

Genetic Insights in GLP-1 Response: What the Science Shows

Research increasingly recognizes that genetic variation in GLP-1 signaling pathways influences medication response. Key variants including GLP1R rs6923761 and GIPR rs1800437 correlate with differential appetite suppression and weight loss trajectories in clinical cohorts. Neither variant guarantees specific outcomes, but understanding individual genotype can support more informed prescriber conversations.

Zealthy's use of genetic testing reflects this emerging evidence base, offering patients and providers a biological lens for treatment planning. However, genetic data alone cannot predict exact medication response—environmental, behavioral, and medical factors remain equally critical. Hers' clinical-only approach remains valid for many candidates, particularly those with clear clinical indication and prior GLP-1 exposure.

Cost, Access, and Insurance Coverage Considerations

Zealthy's comprehensive intake process, including genetic and biomarker testing, typically results in higher upfront costs than Hers' streamlined consultation model. Zealthy charges for genetic analysis and biomarker panels separately from prescription costs, potentially ranging $150–$300 before medication expenses. Hers' simpler model generally offers lower consultation fees but still requires prescription costs through the platform.

Insurance coverage varies widely. Both platforms' prescription components may be partially covered by insurance depending on clinical indication (weight loss vs. type 2 diabetes), while genetic testing is rarely covered. Patients should clarify with each platform whether their insurance plan covers any portion of testing or consultation fees before enrolling.

PlexusDx Precision Peptide Approach: Compounded GLP-1 with Genetic Context

PlexusDx's compounded semaglutide and tirzepatide options ($149/mo) provide an alternative pathway that integrates genetic insight without requiring enrollment in a single-platform model. Our Precision Peptide Genetic Test ($99 add-on or $298 standalone) analyzes the same key variants as premium telehealth platforms, revealing predispositions in GLP1R, GIPR, FTO, and MC4R pathways. This genetic data may help contextualize individual peptide pathway function for provider discussion.

Unlike Zealthy's integrated model, PlexusDx allows patients to obtain genetic testing independently and share results with any qualified prescriber—increasing flexibility and reducing lock-in. Compounded formulations from licensed 503A pharmacies offer dosing customization unavailable through standard branded medications. Patients working with compounding-friendly providers can leverage genetic insights to refine dosing protocols and monitoring strategies tailored to their individual profiles.

Safety, Monitoring, and Ongoing Care

Both Zealthy and Hers require baseline health screening and ongoing provider communication to monitor for GLP-1–related side effects, including gastrointestinal symptoms, pancreatitis risk, and thyroid considerations. Zealthy's biomarker monitoring may support more granular tracking of metabolic markers over time. Hers typically follows standard telehealth monitoring protocols with periodic check-ins and lab orders as needed.

Regardless of platform, patients on GLP-1 therapy benefit from regular provider oversight, especially during dose escalation. Compounded GLP-1 options from PlexusDx require the same level of prescriber engagement and monitoring as branded alternatives. Genetic testing should never replace clinical evaluation—it complements it by offering one additional data layer for informed decision-making.

How PlexusDx Supports a More Personalized Approach

Genetic variation in peptide signaling pathways—particularly GLP1R and GIPR regions—may influence individual tolerance, efficacy, and side-effect profiles. PlexusDx's Precision Peptide Genetic Test reveals genetic predispositions in these pathways, which can support more targeted conversations between patients and their prescribing providers. Importantly, genetic data provides context, not destiny; clinical assessment, lifestyle, and medical history remain equally critical determinants of GLP-1 suitability and response.

The Precision Peptide Genetic Test analyzes four key variants (GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, MC4R rs17782313) known to affect metabolic and appetite-regulation pathways relevant to GLP-1 therapy. Test results may help clarify whether a patient's genetic profile aligns with typical GLP-1 responder characteristics or suggests need for alternative dosing, monitoring, or medication selection. This does not predict exact outcomes but can enrich provider-patient dialogue and treatment planning.

Patients interested in exploring genetic insights alongside compounded GLP-1 therapy can use PlexusDx testing results in conversations with any qualified prescriber. The data becomes part of your clinical record, supporting shared decision-making about whether compounded semaglutide, tirzepatide, or other peptide options align with your individual metabolic profile and goals. PlexusDx supports this precision approach while remaining agnostic about which medication is right for you—that determination belongs to you and your healthcare provider.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Microdose Glp1 Protocol starts at $129/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the main difference between Zealthy and Hers for GLP-1 access?

Zealthy integrates genetic and biomarker testing into its intake workflow to personalize GLP-1 matching, while Hers prioritizes rapid telehealth consultation without genetic prerequisites. Zealthy's genetic approach may reveal peptide pathway predispositions; Hers focuses on straightforward clinical eligibility and prescription delivery.

Does genetic testing guarantee that GLP-1 will work better for me?

No. Genetic variants provide context about peptide pathway function but cannot predict exact medication outcomes. Clinical health status, lifestyle, medication adherence, and individual biology interact in complex ways. Genetic data should inform conversations with your provider, not replace medical evaluation.

How does PlexusDx's genetic test compare to Zealthy's approach?

PlexusDx's Precision Peptide Genetic Test analyzes similar key variants (GLP1R, GIPR, FTO, MC4R) but operates independently of a single platform. You can obtain testing at $99–$298 and share results with any compounding-friendly prescriber, offering flexibility and reduced lock-in compared to Zealthy's integrated model.

Which platform is better for insurance coverage?

Both Zealthy and Hers may qualify for partial insurance coverage if GLP-1 is prescribed for type 2 diabetes or approved weight-loss indication, but coverage varies by plan. Genetic testing is rarely covered by insurance under either platform. Contact your insurer and the platform before enrolling to clarify out-of-pocket costs.

Can I use PlexusDx's genetic test with a Zealthy or Hers prescription?

Possibly. If you obtain PlexusDx Precision Peptide testing independently, you may share results with any prescriber, including those from Zealthy or Hers, to enhance clinical conversations. However, Zealthy has its own integrated genetic protocol, so check with them about incorporating outside genetic data into their workflow.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

learn